Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06680661 · ClinicalTrials.gov registry record · Phase 2

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

A Phase 2 study of Lymphoma and Myelodysplastic Syndromes, sponsored by Leland Metheny.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT06680661 is a Phase 2 study of Lymphoma and Myelodysplastic Syndromes that is actively recruiting participants, run by Leland Metheny. The registered enrollment target is 20 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06680661, a Phase 2 study of Lymphoma and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Leland Metheny.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.

Conditions Studied

Lymphoma Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia Hodgkin Lymphoma Acute Myelogenous Leukemia Chronic Myelogenous Leukemia Acute Lymphatic Leukemia Myelodysplastic Syndrome Other

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG Thiotepa
  • RADIATION Total Body Irradiation
  • BIOLOGICAL Double Umbilical Cord Transplant

Study Locations (1)

Ohio

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-02-25
Est. Completion 2028-10-31
Phase Phase 2

Sponsor

Leland Metheny

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06680661

The ClinicalTrials.gov registry entry for NCT06680661 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The listed sponsor is Leland Metheny, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT06680661 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT06680661 about?

NCT06680661 is a clinical study titled "ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis". The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention...

What is the current status of trial NCT06680661?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-02-25. Estimated completion is 2028-10-31.

What conditions does trial NCT06680661 study?

This clinical trial studies the following conditions: Lymphoma, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Acute Myelogenous Leukemia.

What interventions are being tested in trial NCT06680661?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Thiotepa (DRUG), Total Body Irradiation (RADIATION), Double Umbilical Cord Transplant (BIOLOGICAL).

Who is sponsoring clinical trial NCT06680661?

This trial is sponsored by Leland Metheny, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06680661 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.